{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:36:00Z","timestamp":1776134160459,"version":"3.50.1"},"reference-count":80,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Philadelphia chromosome-negative myeloproliferative neoplasms are hematopoietic stem cell disorders characterized by dysregulated proliferation of mature myeloid blood cells. They can present as polycythemia vera, essential thrombocythemia, or myelofibrosis and are characterized by constitutive activation of JAK2 signaling. They share a propensity for thrombo-hemorrhagic complications and the risk of progression to acute myeloid leukemia. Attention has also been drawn to JAK2 mutant clonal hematopoiesis of indeterminate potential as a possible precursor state of MPN. Insight into the pathogenesis as well as options for the treatment of MPN has increased in the last years thanks to modern sequencing technologies and functional studies. Mutational analysis provides information on the oncogenic driver mutations in JAK2, CALR, or MPL in the majority of MPN patients. In addition, molecular markers enable more detailed prognostication and provide guidance for therapeutic decisions. While JAK2 inhibitors represent a standard of care for MF and resistant\/refractory PV, allogeneic hematopoietic stem cell transplantation remains the only therapy with a curative potential in MPN so far but is reserved to a subset of patients. Thus, novel concepts for therapy are an important need, particularly in MF. Novel JAK2 inhibitors, combination therapy approaches with ruxolitinib, as well as therapeutic approaches addressing new molecular targets are in development. Current standards and recent advantages are discussed in this review.<\/jats:p>","DOI":"10.1055\/a-1447-6667","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T22:49:22Z","timestamp":1625093362000},"page":"197-205","source":"Crossref","is-referenced-by-count":4,"title":["Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms"],"prefix":"10.1055","volume":"41","author":[{"given":"Franziska C.","family":"Zeeh","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Basel, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara C.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Basel, Basel, Switzerland"},{"name":"Division of Hematology and Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"issue":"22","key":"ref1","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"J L Spivak","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"ref2","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"R Rampal","year":"2014","journal-title":"Blood"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"S Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1097\/HS9.0000000000000516","article-title":"Challenges and perspectives for therapeutic targeting of myeloproliferative neoplasms","volume":"5","author":"S Brkic","year":"2020","journal-title":"HemaSphere"},{"issue":"08","key":"ref5","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-13-0279","article-title":"Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors","volume":"20","author":"S C Meyer","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"08","key":"ref6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.exphem.2015.06.007","article-title":"Pathogenesis of myeloproliferative neoplasms","volume":"43","author":"R C Skoda","year":"2015","journal-title":"Exp Hematol"},{"issue":"23","key":"ref7","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.3346\/jkms.2020.35.e168","article-title":"A rare case of essential thrombocythemia with coexisting JAK2 and MPL driver mutations","volume":"35","author":"M A Jang","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjh.15954","article-title":"Next generation sequencing redefines a triple negative essential thrombocythaemia as double-positive with rare mutations on JAK2\u2009V617 and MPL W515 hotspots","volume":"186","author":"A Beucher","year":"2019","journal-title":"Br J Haematol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"C James","year":"2005","journal-title":"Nature"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"R L Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"17","key":"ref11","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"R Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"E J Baxter","year":"2005","journal-title":"Lancet"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"L M Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Y Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"A D Pardanani","year":"2006","journal-title":"Blood"},{"issue":"25","key":"ref16","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"T Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"ref17","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"J Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"S Elf","year":"2016","journal-title":"Cancer Discov"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"A Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"X Cabagnols","year":"2016","journal-title":"Blood"},{"issue":"14","key":"ref21","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"P Lundberg","year":"2014","journal-title":"Blood"},{"issue":"15","key":"ref22","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"J Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"07","key":"ref23","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"O Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"50","key":"ref24","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"R Rampal","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"33","key":"ref25","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"R M Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"ref26","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"D A Arber","year":"2016","journal-title":"Blood"},{"issue":"21","key":"ref27","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification","volume":"117","author":"J Thiele","year":"2011","journal-title":"Blood"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"L Busque","year":"2012","journal-title":"Nat Genet"},{"issue":"26","key":"ref29","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"S Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"ref30","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"L Malcovati","year":"2017","journal-title":"Blood"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"S Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"ref32","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1182\/bloodadvances.2017007047","article-title":"JAK2\u2009V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics","volume":"1","author":"T McKerrell","year":"2017","journal-title":"Blood Adv"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"T Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"R Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"R Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","article-title":"White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study","volume":"126","author":"T Barbui","year":"2015","journal-title":"Blood"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","article-title":"Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation","volume":"138","author":"N Gangat","year":"2007","journal-title":"Br J Haematol"},{"issue":"09","key":"ref38","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"F Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"G Barosi","year":"2010","journal-title":"Br J Haematol"},{"issue":"08","key":"ref40","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"J J Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"H Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"05","key":"ref42","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"A M Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"F Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"02","key":"ref44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"B Rocca","year":"2020","journal-title":"Blood"},{"issue":"08","key":"ref45","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"A Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"issue":"26","key":"ref46","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"T Barbui","year":"2012","journal-title":"Blood"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients","volume":"91","author":"M Haider","year":"2016","journal-title":"Am J Hematol"},{"issue":"06","key":"ref48","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"F Passamonti","year":"2012","journal-title":"Blood"},{"issue":"16","key":"ref49","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"A Carobbio","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref50","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis","volume":"3","author":"A Carobbio","year":"2019","journal-title":"Blood Adv"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"C N Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"ref52","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"H Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/bjh.15824","article-title":"A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2\u00b70 trial","volume":"185","author":"H Gisslinger","year":"2019","journal-title":"Br J Haematol"},{"issue":"17","key":"ref54","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"C N Harrison","year":"2017","journal-title":"Blood"},{"issue":"23","key":"ref55","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/blood.2019001861","article-title":"The poor outcome in high molecular risk, hydroxycarbamide-resistant\/intolerant ET is not ameliorated by ruxolitinib","volume":"134","author":"J M O'Sullivan","year":"2019","journal-title":"Blood"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"A Tefferi","year":"2021","journal-title":"Am J Hematol"},{"issue":"09","key":"ref57","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"F Passamonti","year":"2010","journal-title":"Blood"},{"issue":"04","key":"ref58","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"N Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"P Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"ref60","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"A Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"07","key":"ref61","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"A Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"ref62","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","article-title":"Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results","volume":"94","author":"F Cervantes","year":"2015","journal-title":"Ann Hematol"},{"issue":"09","key":"ref63","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"S Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"09","key":"ref64","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"C Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"01","key":"ref65","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"S Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"12","key":"ref66","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","article-title":"Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients","volume":"89","author":"A Mart\u00ednez-Trillos","year":"2010","journal-title":"Ann Hematol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"284706","DOI":"10.1155\/2015\/284706","article-title":"Impact of inflammation on myeloproliferative neoplasm symptom development","volume":"2015","author":"H L Geyer","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"03","key":"ref68","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"M Kleppe","year":"2015","journal-title":"Cancer Discov"},{"issue":"07","key":"ref69","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"E Porpaczy","year":"2018","journal-title":"Blood"},{"issue":"12","key":"ref70","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"A Tefferi","year":"2011","journal-title":"Mayo Clin Proc"},{"issue":"01","key":"ref71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-020-00392-1","article-title":"Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis","volume":"11","author":"F Palandri","year":"2021","journal-title":"Blood Cancer J"},{"issue":"11","key":"ref72","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"N M Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"issue":"05","key":"ref73","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"A Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"C N Harrison","year":"2020","journal-title":"Am J Hematol"},{"issue":"08","key":"ref75","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","article-title":"Fedratinib in myelofibrosis","volume":"4","author":"A Mullally","year":"2020","journal-title":"Blood Adv"},{"issue":"02","key":"ref76","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"C N Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"05","key":"ref77","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"J Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"04","key":"ref78","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"M Waibel","year":"2013","journal-title":"Cell Rep"},{"issue":"10","key":"ref79","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"A Tefferi","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"ref80","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor imetelstat in patients with essential thrombocythemia","volume":"373","author":"G M Baerlocher","year":"2015","journal-title":"N Engl J Med"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1447-6667.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T22:50:12Z","timestamp":1625093412000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1447-6667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":80,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2021,6,30]]},"published-print":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1447-6667","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}